Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease
Alzheimer's disease (AD) is considered the most common and prevalent form of dementia of adult-onset with characteristic progressive impairment in cognition and memory. The cure for AD has not been found yet and the treatments available until recently were only symptomatic. Regardless of multid...
Saved in:
Main Author: | Alvaro Barrera-Ocampo (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Monoclonal Antibody Therapy in Alzheimer's Disease
by: Monica Neațu, et al.
Published: (2023) -
Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer's Disease
by: Maria Teresa Cruz, et al.
Published: (2022) -
Monoclonal antibodies for Alzheimer disease: statistical significance vs clinical efficacy
by: Einstein Francisco Camargos, et al.
Published: (2024) -
Monoclonal Antibodies as Neurological Therapeutics
by: Panagiotis Gklinos, et al.
Published: (2021) -
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
by: Brian Kelley
Published: (2024)